International expert consensus on primary systemic therapy in the management of early breast cancer

Highlights of the fourth symposium on primary systemic therapy in the management of operable breast cancer, Cremona, Italy (2010)

Alfredo Berruti, Daniele Generali, Manfred Kaufmann, Lajos Puztai, Giuseppe Curigliano, Massimo Aglietta, Luca Gianni, William R. Miller, Michael Untch, Christos Sotiriou, Mariagrazia Daidone, PierFranco Conte, Derek Kennedy, Giovanna Damia, Piergiorgio Petronini, Serena Di Cosimo, Paolo Bruzzi, Mitch Dowsett, Christine Desmedt, Robert E. Mansel & 19 others Lucio Olivetti, Carlo Tondini, Anna Sapino, Privato Fenaroli, Gianpaolo Tortora, Hather Thorne, Francesco Bertolini, Francesco Ferrozzi, Marco Danova, Elda Tagliabue, Evandro de Azambuja, Andreas Makris, Marco Tampellini, Gabriela Dontu, Laura Van t Veer, Adrian L. Harris, Stephen B. Fox, Luigi Dogliotti, Alberto Bottini

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

A panel of international breast cancer experts formulated a declaration of consensus regarding many key issues in the use of primary systemic therapy (PST) either in clinical routine or research practice. The attainment of pathological complete response (pCR), defined as no residual invasive tumor in the surgical specimens both in breast and in axillary nodes, is one of the main goals of PST, and pCR can be used as the primary objective in prospective clinical trials. However, pCR is not a reliable endpoint with all treatment approaches, and alternatives such as Ki67 index of the residual invasive disease or after 2 weeks of PST are also potential endpoints. PST has several advantages: breast conservation and the unique opportunity to obtain information on the interaction between treatment and tumor biology. Changes in tumor biology after PST are an early phenomenon; so, an additional core biopsy performed after 14 days from treatment start should be considered in clinical trials.

Original languageEnglish
Pages (from-to)147-151
Number of pages5
JournalJournal of the National Cancer Institute - Monographs
Issue number43
DOIs
Publication statusPublished - Oct 2011

Fingerprint

Italy
Breast Neoplasms
Breast
Clinical Trials
Therapeutics
Residual Neoplasm
Neoplasms
Biopsy
Research

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

International expert consensus on primary systemic therapy in the management of early breast cancer : Highlights of the fourth symposium on primary systemic therapy in the management of operable breast cancer, Cremona, Italy (2010). / Berruti, Alfredo; Generali, Daniele; Kaufmann, Manfred; Puztai, Lajos; Curigliano, Giuseppe; Aglietta, Massimo; Gianni, Luca; Miller, William R.; Untch, Michael; Sotiriou, Christos; Daidone, Mariagrazia; Conte, PierFranco; Kennedy, Derek; Damia, Giovanna; Petronini, Piergiorgio; Di Cosimo, Serena; Bruzzi, Paolo; Dowsett, Mitch; Desmedt, Christine; Mansel, Robert E.; Olivetti, Lucio; Tondini, Carlo; Sapino, Anna; Fenaroli, Privato; Tortora, Gianpaolo; Thorne, Hather; Bertolini, Francesco; Ferrozzi, Francesco; Danova, Marco; Tagliabue, Elda; de Azambuja, Evandro; Makris, Andreas; Tampellini, Marco; Dontu, Gabriela; Veer, Laura Van t; Harris, Adrian L.; Fox, Stephen B.; Dogliotti, Luigi; Bottini, Alberto.

In: Journal of the National Cancer Institute - Monographs, No. 43, 10.2011, p. 147-151.

Research output: Contribution to journalArticle

Berruti, A, Generali, D, Kaufmann, M, Puztai, L, Curigliano, G, Aglietta, M, Gianni, L, Miller, WR, Untch, M, Sotiriou, C, Daidone, M, Conte, P, Kennedy, D, Damia, G, Petronini, P, Di Cosimo, S, Bruzzi, P, Dowsett, M, Desmedt, C, Mansel, RE, Olivetti, L, Tondini, C, Sapino, A, Fenaroli, P, Tortora, G, Thorne, H, Bertolini, F, Ferrozzi, F, Danova, M, Tagliabue, E, de Azambuja, E, Makris, A, Tampellini, M, Dontu, G, Veer, LVT, Harris, AL, Fox, SB, Dogliotti, L & Bottini, A 2011, 'International expert consensus on primary systemic therapy in the management of early breast cancer: Highlights of the fourth symposium on primary systemic therapy in the management of operable breast cancer, Cremona, Italy (2010)', Journal of the National Cancer Institute - Monographs, no. 43, pp. 147-151. https://doi.org/10.1093/jncimonographs/lgr037
Berruti, Alfredo ; Generali, Daniele ; Kaufmann, Manfred ; Puztai, Lajos ; Curigliano, Giuseppe ; Aglietta, Massimo ; Gianni, Luca ; Miller, William R. ; Untch, Michael ; Sotiriou, Christos ; Daidone, Mariagrazia ; Conte, PierFranco ; Kennedy, Derek ; Damia, Giovanna ; Petronini, Piergiorgio ; Di Cosimo, Serena ; Bruzzi, Paolo ; Dowsett, Mitch ; Desmedt, Christine ; Mansel, Robert E. ; Olivetti, Lucio ; Tondini, Carlo ; Sapino, Anna ; Fenaroli, Privato ; Tortora, Gianpaolo ; Thorne, Hather ; Bertolini, Francesco ; Ferrozzi, Francesco ; Danova, Marco ; Tagliabue, Elda ; de Azambuja, Evandro ; Makris, Andreas ; Tampellini, Marco ; Dontu, Gabriela ; Veer, Laura Van t ; Harris, Adrian L. ; Fox, Stephen B. ; Dogliotti, Luigi ; Bottini, Alberto. / International expert consensus on primary systemic therapy in the management of early breast cancer : Highlights of the fourth symposium on primary systemic therapy in the management of operable breast cancer, Cremona, Italy (2010). In: Journal of the National Cancer Institute - Monographs. 2011 ; No. 43. pp. 147-151.
@article{aa81196a373d41ac98e9f568ecd955f6,
title = "International expert consensus on primary systemic therapy in the management of early breast cancer: Highlights of the fourth symposium on primary systemic therapy in the management of operable breast cancer, Cremona, Italy (2010)",
abstract = "A panel of international breast cancer experts formulated a declaration of consensus regarding many key issues in the use of primary systemic therapy (PST) either in clinical routine or research practice. The attainment of pathological complete response (pCR), defined as no residual invasive tumor in the surgical specimens both in breast and in axillary nodes, is one of the main goals of PST, and pCR can be used as the primary objective in prospective clinical trials. However, pCR is not a reliable endpoint with all treatment approaches, and alternatives such as Ki67 index of the residual invasive disease or after 2 weeks of PST are also potential endpoints. PST has several advantages: breast conservation and the unique opportunity to obtain information on the interaction between treatment and tumor biology. Changes in tumor biology after PST are an early phenomenon; so, an additional core biopsy performed after 14 days from treatment start should be considered in clinical trials.",
author = "Alfredo Berruti and Daniele Generali and Manfred Kaufmann and Lajos Puztai and Giuseppe Curigliano and Massimo Aglietta and Luca Gianni and Miller, {William R.} and Michael Untch and Christos Sotiriou and Mariagrazia Daidone and PierFranco Conte and Derek Kennedy and Giovanna Damia and Piergiorgio Petronini and {Di Cosimo}, Serena and Paolo Bruzzi and Mitch Dowsett and Christine Desmedt and Mansel, {Robert E.} and Lucio Olivetti and Carlo Tondini and Anna Sapino and Privato Fenaroli and Gianpaolo Tortora and Hather Thorne and Francesco Bertolini and Francesco Ferrozzi and Marco Danova and Elda Tagliabue and {de Azambuja}, Evandro and Andreas Makris and Marco Tampellini and Gabriela Dontu and Veer, {Laura Van t} and Harris, {Adrian L.} and Fox, {Stephen B.} and Luigi Dogliotti and Alberto Bottini",
year = "2011",
month = "10",
doi = "10.1093/jncimonographs/lgr037",
language = "English",
pages = "147--151",
journal = "Journal of the National Cancer Institute. Monographs",
issn = "1052-6773",
publisher = "Oxford University Press",
number = "43",

}

TY - JOUR

T1 - International expert consensus on primary systemic therapy in the management of early breast cancer

T2 - Highlights of the fourth symposium on primary systemic therapy in the management of operable breast cancer, Cremona, Italy (2010)

AU - Berruti, Alfredo

AU - Generali, Daniele

AU - Kaufmann, Manfred

AU - Puztai, Lajos

AU - Curigliano, Giuseppe

AU - Aglietta, Massimo

AU - Gianni, Luca

AU - Miller, William R.

AU - Untch, Michael

AU - Sotiriou, Christos

AU - Daidone, Mariagrazia

AU - Conte, PierFranco

AU - Kennedy, Derek

AU - Damia, Giovanna

AU - Petronini, Piergiorgio

AU - Di Cosimo, Serena

AU - Bruzzi, Paolo

AU - Dowsett, Mitch

AU - Desmedt, Christine

AU - Mansel, Robert E.

AU - Olivetti, Lucio

AU - Tondini, Carlo

AU - Sapino, Anna

AU - Fenaroli, Privato

AU - Tortora, Gianpaolo

AU - Thorne, Hather

AU - Bertolini, Francesco

AU - Ferrozzi, Francesco

AU - Danova, Marco

AU - Tagliabue, Elda

AU - de Azambuja, Evandro

AU - Makris, Andreas

AU - Tampellini, Marco

AU - Dontu, Gabriela

AU - Veer, Laura Van t

AU - Harris, Adrian L.

AU - Fox, Stephen B.

AU - Dogliotti, Luigi

AU - Bottini, Alberto

PY - 2011/10

Y1 - 2011/10

N2 - A panel of international breast cancer experts formulated a declaration of consensus regarding many key issues in the use of primary systemic therapy (PST) either in clinical routine or research practice. The attainment of pathological complete response (pCR), defined as no residual invasive tumor in the surgical specimens both in breast and in axillary nodes, is one of the main goals of PST, and pCR can be used as the primary objective in prospective clinical trials. However, pCR is not a reliable endpoint with all treatment approaches, and alternatives such as Ki67 index of the residual invasive disease or after 2 weeks of PST are also potential endpoints. PST has several advantages: breast conservation and the unique opportunity to obtain information on the interaction between treatment and tumor biology. Changes in tumor biology after PST are an early phenomenon; so, an additional core biopsy performed after 14 days from treatment start should be considered in clinical trials.

AB - A panel of international breast cancer experts formulated a declaration of consensus regarding many key issues in the use of primary systemic therapy (PST) either in clinical routine or research practice. The attainment of pathological complete response (pCR), defined as no residual invasive tumor in the surgical specimens both in breast and in axillary nodes, is one of the main goals of PST, and pCR can be used as the primary objective in prospective clinical trials. However, pCR is not a reliable endpoint with all treatment approaches, and alternatives such as Ki67 index of the residual invasive disease or after 2 weeks of PST are also potential endpoints. PST has several advantages: breast conservation and the unique opportunity to obtain information on the interaction between treatment and tumor biology. Changes in tumor biology after PST are an early phenomenon; so, an additional core biopsy performed after 14 days from treatment start should be considered in clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=84855180116&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855180116&partnerID=8YFLogxK

U2 - 10.1093/jncimonographs/lgr037

DO - 10.1093/jncimonographs/lgr037

M3 - Article

SP - 147

EP - 151

JO - Journal of the National Cancer Institute. Monographs

JF - Journal of the National Cancer Institute. Monographs

SN - 1052-6773

IS - 43

ER -